Facebook
Twitter
LinkedIn
Forward
The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis & Treatment
The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with this condition. Compared to men, women with HF receive suboptimal guideline-directed medical therapy (GDMT), including medications, implantable cardioverter defibrillators, ventricular assist devices, or heart transplant. Additionally, despite a higher HF symptom burden, women are frequently misdiagnosed and also underrepresented in HF clinical trials, which further exacerbates these gaps. In recent years, significant advances in the prevention and treatment of HF across the ejection fraction spectrum have been made, all with the potential to alter treatment paradigms now and in the future.
In this activity, experts review some of these gaps, as well as discuss how to apply the recent advances to improve the care of women with HF. To walk you through these updates, this interactive infographic activity utlizes high-impact visuals, as well as added expert perspectives, all designed to help you engage with the content better.
Target Audience
The educational design of this activity addresses the needs of U.S. based endocrinologists, cardiologists, internists, primary care clinicians, obstetricians, pharmacists, physicians, nurse practitioners, and physician assistants.
Learning Objectives
After completing this activity, the participant should be better able to:
- Discuss the burden of HF in women, as well as differences in HF etiology and risk factors.
- Recognize the differences in HF symptom presentation in women in order to identify HF in a timely manner.
- Summarize important differences and considerations for the application of GDMT in women with HF.
- Review the efficacy and safety of new and emerging therapies for the treatment of women with HFrEF or HFpEF.
- Individualize therapy for women with HFrEF or HFpEF according to evidence-based strategies and patient specific risk factors.
Additional Information
| Attachment | Size |
|---|---|
 Treatment of HF | 1.36 MB |
| Sex-Specific Considerations on HF Therapies | 327.12 KB |
| HF Risk Factors & HF Presentation in Women | 3.17 MB |
Pam R. Taub, MD, FACC, FASPC (Chair)
Professor of Medicine
Director, Step Family Foundation Cardiac
Rehabilitation and Wellness Center
UC San Diego
San Diego, CA
Dr. Taub discloses the following:
Consulting Fee (e.g., Advisory Board): Amgen, Bayer, Boehringer-Ingelheim, Esperion therapeutics, Medtronic, Novartis, Novo-Nordisk, Sanofi
Honororia: Epirium Bio
Contracted Research: Applied Therapeutics
Michelle M. Kittleson, MD, PhD
Professor of Medicine Smidt Heart Institute, Cedars-Sinai
Los Angeles, CA
Dr. Kittleson has nothing to disclose.
Barry H. Greenberg, MD
Director, Advanced Heart Failure Treatment Program
University of California
San Diego, CA
Dr. Greenberg discloses the following:
- Consulting Fee (e.g., Advisory Board): AstraZeneca, Bayer, Cytokinetics, Ionis, Merck, Tenaya
- Contracted Research: Rocket Pharma
- Honoraria: ACI, Axon, BoerhingerIngelheim, Cytokinetics, EBR Systems, Impulse Dynamics, Inventiva, Ionis, Salubris, Vifor, VIking, Windtree
Anuradha Lala-Trindade (Anu Lala), MD
Associate Professor, Icahn School of Medicine at Mount Sinai
The Zena and Michael A. Wiener Cardiovascular Institute
Department of Health Population Science and Statistics
New York, NY
Dr. Lala discloses the following:
Consulting Fee (e.g., Advisory Board): Merck, Astra Zeneca, Cytokinetics, Novartis
Honoraria: Merck, Astra Zeneca, Cytokinetics, Novartis
ESTIMATED TIME TO COMPLETE ACTIVITY
1.0 hours
EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.
JOINT PROVIDERSHIP STATEMENT
This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians
PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACIST ACCREDITATION STATEMENT
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number (UAN): 0530-9999-22-113-H01-P.
This is a knowledge-based activity.
GLOBAL CONTACT INFORMATION
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com..
DISCLOSURES
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The planners and managers have the following relevant financial relationships with ineligible companies:
| Name of Planner or Manager | Reported Financial Relationship |
| Rhys Williams, MSN, FNP-C, RN | Nothing to disclose. |
| Lauren Sinclair | Nothing to disclose. |
| Lindsay Borvansky | Nothing to disclose. |
| Liddy Knight | Nothing to disclose. |
| Andrea Funk | Nothing to disclose. |
| Ashley Cann | Nothing to disclose. |
| Deborah Sharkey | Nothing to disclose. |
| Kelly Pechous | Nothing to disclose. |
| Karin McAdams | Nothing to disclose. |
| Shpetim Karandrea, PhD | Nothing to disclose. |
| Neha Agarwal, PhD | Nothing to disclose. |
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
This activity is complimentary and available during the period January 27, 2023 through January 27, 2024. Participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 70% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
Available Credit
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
Required Hardware/software
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.